A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs MK 1308 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 16 Feb 2018 Planned number of patients changed from 148 to 168.
- 16 Feb 2018 Planned End Date changed from 4 Mar 2019 to 20 Sep 2020.
- 16 Feb 2018 Planned primary completion date changed from 4 Mar 2019 to 20 Sep 2020.